Description: Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in Newton, Massachusetts.
Home Page: www.stealthbt.com
MITO Technical Analysis
190 Elgin Avenue
George Town,
KY1-9005
Cayman Islands
Phone:
617-600-6888
Officers
| Name | Title |
|---|---|
| Ms. Irene P. McCarthy J.D. | Pres ,CEO, Sec. & Director |
| Mr. Henry Hess | Chief Legal Counsel |
| Dr. Ben R. Bronstein M.D. | Chief Medical Officer |
| Mr. Brian Hotchkiss | VP of Bus. Devel. & Strategy |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 36.5663 |
| Price-to-Sales TTM: | 3.0313 |
| IPO Date: | 2019-02-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |